Magic mushroom compound tested for OCD relief
NCT ID NCT06992999
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This early-phase study will give 20 adults with obsessive-compulsive disorder (OCD) either a low or high dose of psilocybin, the active ingredient in magic mushrooms, in four supervised sessions. Researchers will track changes in OCD symptoms, brain activity, and safety over 12 weeks. The goal is to see if psilocybin can ease OCD symptoms and improve daily functioning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Arizona-Tucson
Tucson, Arizona, 85724, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.